Alpha tocopherol, a fat-soluble vitamin and antioxidant, has been studied in patients with moderately severe Alzheimer disease (AD)
1 and in participants with mild cognitive impairment (MCI)
2 but has not been studied in patients with mild to moderate AD. In patients with moderately severe AD,
1 alpha tocopherol (2000 IU/d) was shown to be effective in slowing clinical progression. In participants with MCI,
2 however, alpha tocopherol (2000 IU/d) had no benefit compared with placebo in reducing the rate of conversion to AD.